Entering text into the input field will update the search result below

Sorrento granted FDA nod to start clinical trial for intranasal COVID-19 therapy

Mar. 02, 2022 12:02 PM ETSorrento Therapeutics, Inc. (SRNEQ)By: Dulan Lokuwithana, SA News Editor6 Comments

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • San Diego, California-based biotech Sorrento Therapeutics (SRNE +1.2%) announced on Wednesday that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application (IND) for intranasal STI-9199 (COVISHIELD), an experimental antibody against COVID-19.

Recommended For You

Comments (6)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

prudent 576 profile picture
SRNE is a pump n' dump stock which I have made money on in the past. Wait until it gets down to about $1.50, buy and sell when it is sufficiently pumped. It is clear when you look at the past 22-year chart. You're welcome.
This Phase1 or vitro king stock will be less than 1$ soon. Their CEO is PR guy pumping share prices with vitro results for every week. SRNE pipeline is like a giant pharma company because they announce vitro or p1 studies.
2 years into COVID and we are just at phase one for this treatment. I bought into SRNE in early 2021 partly because I’m on board with COVID therapies and love the direction.... just scratching my head at the glacial pace of progress.

Seems the entire pipeline is on the same, slow trajectory. Frustratingly slow and I’ve been staring at red for months. And I realize one reason for the red is the shenanigans the shorts are playing but until there is tangible news they continue to have the upper hand.
Down 547% on the news.... so much more than a covid play, so misunderstood
@goodfellasfinancial so explain it for me. I read a lot of negatives about the company. What’s the positive (beyond hoping)?
arvsha16 profile picture
@flat baroque nothing, just PR every week I feel.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.